Rosa De Abreu Ferreira

Atogepant for the preventive treatment of chronic migraine (PROGRESS): a randomised, double-blind, placebo-controlled, phase 3 trial

Patricia Pozo‐Rosich, Jessica Ailani, Messoud Ashina et al. · The Lancet · 2023 · 133 citations

Medicine, Neurology, Preventive Medicine +9

Safety and efficacy of atogepant for the preventive treatment of episodic migraine in adults for whom conventional oral preventive treatments have failed (ELEVATE): a randomised, placebo-controlled, phase 3b trial

Cristina Tassorelli, Krisztián Nagy, Patricia Pozo‐Rosich et al. · The Lancet Neurology · 2024 · 75 citations

Pharmacy, Pharmacotherapy, Preventive Medicine +12

Phase Ib, open‐label, fixed‐sequence, drug–drug interaction, safety, and tolerability study between atogepant and ubrogepant in participants with a history of migraine

Andrew Blumenfeld, Ramesh Boinpally, Rosa De Abreu Ferreira et al. · Headache The Journal of Head and Face Pain · 2023 · 17 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

A Pilot, Predictive Surveillance Model in Pharmacovigilance Using Machine Learning Approaches

Rosa De Abreu Ferreira, Sheng Zhong, Charlotte Moureaud et al. · Advances in Therapy · 2024 · 12 citations · Full text

Pharmacy, Data Science, Pharmacology +17

Safety and tolerability of ubrogepant for the acute treatment of migraine in participants taking atogepant for the preventive treatment of episodic migraine: Results from the <scp>TANDEM</scp> study

Jessica Ailani, Richard Lipton, Andrew Blumenfeld et al. · Headache The Journal of Head and Face Pain · 2024 · 11 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +14